4-(5-羟基吡啶-2-基)哌嗪-1-羧酸叔丁酯 | 1211542-18-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 4-(5-羟基吡啶-2-基)哌嗪-1-羧酸叔丁酯
• 英文名称: tert-butyl 4-(5-hydroxypyridin-2-yl)piperazine-1-carboxylate
• 英文别名: Tert-butyl 4-(5-hydroxypyridin-2-YL)piperazine-1-carboxylate
• CAS: 1211542-18-5
• 化学式: C₁₄H₂₁N₃O₃
• 分子量: 279.339
• InChiKey: PSCCGROQUOHWRG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  65.9
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  4-(5-羟基吡啶-2-基)哌嗪-1-羧酸叔丁酯 在 sodium hydride 、 potassium carbonate 、 三氟乙酸 、 potassium iodide 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.5h， 生成 3-[6-[4-(3-Aminopropyl)piperazin-1-yl]pyridin-3-yl]oxypiperidine-2,6-dione
  参考文献：
  名称：

  [EN] INDOLONE DERIVATIVE AND USE THEREOF
  [FR] DÉRIVÉ D'INDOLONE ET SON UTILISATION
  [ZH] 一种吲哚酮衍生物及其应用

  摘要：

  本发明涉及吲哚酮衍生物及其应用，该吲哚酮衍生物能够增强靶蛋白降解，可用于制备抗肿瘤药物。

  公开号：

  WO2024017372A1
• 作为产物：
  描述：

  6-(4-Boc-1-哌嗪并)吡啶-3-硼酸频哪醇酯 在 sodium peroxoborate tetrahydrate 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 16.0h， 生成 4-(5-羟基吡啶-2-基)哌嗪-1-羧酸叔丁酯
  参考文献：
  名称：

  Use of Small-Molecule Crystal Structures To Address Solubility in a Novel Series of G Protein Coupled Receptor 119 Agonists: Optimization of a Lead and in Vivo Evaluation

  摘要：

  G protein coupled receptor 119 (GPR119) is viewed as an attractive target for the treatment of type 2 diabetes and other elements of the metabolic syndrome. During a program toward discovering agonists of GPR119, we herein describe optimization of an initial lead compound, 2, into a development candidate, 42. A key challenge in this program of work was the insolubility of the lead compound. Small-molecule crystallography was utilized to understand the intermolecular interactions in the solid state and resulted in a switch from an aryl sulphone to a 3-cyanopyridyl motif. The compound was shown to be effective in wild-type but not knockout animals, confirming that the biological effects were due to GPR119 agonism.

  DOI：

  10.1021/jm300310c

文献信息

• CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME
  申请人：Arvinas, Inc.

  公开号：US20180215731A1

  公开（公告）日：2018-08-02

  The description relates to cereblon E3 ligase binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present disclosure. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.

  该描述涉及cereblon E3连接酶结合化合物，包括包含相同成分的双功能化合物，这些化合物作为靶向泛素化的调节剂具有实用价值，尤其是抑制剂，可降解和/或以其他方式抑制根据本公开的双功能化合物。特别是，该描述提供了化合物，其一端含有与cereblon E3泛素连接酶结合的配体，另一端含有与目标蛋白结合的部分，使目标蛋白位于泛素连接酶附近以降解（和抑制）该蛋白。可以合成表现出广泛药理活性的化合物，与几乎所有类型的靶向多肽的降解/抑制一致。
• TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS
  申请人：Arvinas, Inc.

  公开号：US20180155322A1

  公开（公告）日：2018-06-07

  The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, Inhibitors of Apoptosis Proteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，这些化合物可用作雌激素受体（目标蛋白）的调节剂。特别是，本公开涉及包含在一段至少有一种Von Hippel-Lindau配体、一种cereblon配体、凋亡抑制蛋白配体、小鼠双分钟同源2配体或其组合的双功能化合物，这些配体与相应的E3泛素连接酶结合，在另一端有一个与目标蛋白结合的部分，使得目标蛋白被置于泛素连接酶附近，以实现目标蛋白的降解（和抑制）。本公开展示了与目标蛋白降解/抑制相关的广泛药理活性。可以通过本公开的化合物和组合物治疗或预防由目标蛋白聚集或积累引起的疾病或障碍。
• [EN] ADENOSINE 2 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RÉCEPTEUR DE L'ADÉNOSINE 2
  申请人：NEKTAR THERAPEUTICS

  公开号：WO2020227156A1

  公开（公告）日：2020-11-12

  The instant disclosure provides novel adenosine receptor antagonist compounds, compositions, methods of making and methods of using. In a further aspect, a method of treating a subject in need thereof, comprising administering a therapeutically effective amount of any one or more of the compounds described herein. In some embodiments, the subject has cancer and the method is a method of treating cancer.

  即时披露提供了新型腺苷受体拮抗剂化合物、组合物、制备方法和使用方法。在另一个方面，一种治疗需要的受试者的方法，包括向受试者施用本文描述的任何一个或多个化合物的治疗有效量。在某些实施例中，受试者患有癌症，该方法是一种治疗癌症的方法。
• [EN] SELECTIVE NR2B ANTAGONISTS<br/>[FR] ANTAGONISTES SÉLECTIFS DE NR2B
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2017066366A1

  公开（公告）日：2017-04-20

  The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

  该披露通常涉及到式I的化合物，包括它们的盐，以及使用这些化合物的组合物和方法。这些化合物是NR2B受体的配体，可能对中枢神经系统的各种疾病的治疗有用。
• [EN] 6,7 - DIHYDROIMIDAZO [2, 1 - B] [1, 3] OXAZINE BACTERICIDES<br/>[FR] BACTÉRICIDES À BASE DE 6,7-DIHYDROIMIDAZO [2,1-B][1,3] OXAZINE
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2012141338A1

  公开（公告）日：2012-10-18

  The present invention provides a novel 6,7-dihydroimidazo[2,1-b][1,3]oxazine compound that has excellent bactericidal action against tubercle bacilli, multidrug-resistant tubercle bacilli, and atypical acid-fast bacilli. Specifically, the present invention provides a compound represented by Formula (1): or a salt thereof, wherein R1 represents tetrahydroisoquinolyl, tetrahydroquinolyl, tetrahydrobenzoazepinyl, benzoxazolyl, benzothiazolyl, indolyl, isoindolinyl, naphthyl, quinolyl, phenyl, biphenylyl, or pyridyl, these groups being optionally substituted, the phenyl, biphenylyl, and pyridyl represented by R1 each being substituted directly or via a linker with at least one group selected from the group consisting of tetrahydropyridyl, diazepanyl, diazabicycloheptanyl, tetrahydrotriazolopyrazinyl, tetrahydroimidazopyrazinyl, azabicyclooctanyl, oxazolyl, piperazinyl, piperidyl, thiazolyl, and the like, each of these groups being optionally substituted; and R2 represents hydrogen or lower alkyl. The present invention further provides a pharmaceutical composition containing the above.

  本发明提供了一种新型的6,7-二氢咪唑[2,1-b][1,3]噁嗪化合物，该化合物对结核分枝杆菌、多药耐药结核分枝杆菌和非典型抗酸杆菌具有优异的杀菌作用。具体而言，本发明提供了一种由式(1)表示的化合物或其盐，其中R1代表四氢异喹啉基、四氢喹啉基、四氢苯并氮杂环庚基、苯并噁唑基、苯并噻唑基、吲哚基、异吲哚啉基、萘基、喹啉基、苯基、联苯基或吡啶基，这些基团可选地被取代，其中R1表示的苯基、联苯基和吡啶基通过连接基直接或经过至少一种从四氢吡啶基、二氮杂环庚基、二氮杂双环庚基、四氢三唑吡嗪基、四氢咪唑吡嗪基、氮杂双环辛基、噁唑基、哌嗪基、哌啶基、噻唑基等基团中选取的至少一种基团进行取代，这些基团可选地被取代；R2代表氢或低碳基。本发明还提供了包含上述化合物的药物组合物。